Maven Biotechnologies is a biotechnology startup founded in 2000 with a focus on transforming respiratory, infectious, and autoimmune disease with Point of Care diagnostics. The company's In-Vitro Diagnostic systems bring respiratory, infectious disease, and autoimmune diagnostic panels to Point of Care, offering a unique approach to healthcare.
One of Maven's key offerings is its test panels, which can screen for hundreds of antibody or protein biomarkers in a single drop of blood, delivering precise diagnoses in minutes. This innovative approach has the potential to revolutionize the diagnosis and treatment of various diseases, potentially leading to significant advancements in the healthcare industry.
With its last investment totaling $1.96M in the form of a grant at 04 October 2010, Maven Biotechnologies received funding from the National Institutes of Health, demonstrating recognition and support from reputable sources within the industry.
Overall, Maven Biotechnologies operates within the Big Data, Biotechnology, and Health Care industries, positioning itself as a promising player in the intersection of technology and healthcare with its innovative approach to diagnostic solutions.
